{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010758","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.051076+00:00","generated_at":"2026-06-17T09:39:57.032329+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Candel Therapeutics Q4 2022 net loss $5.1M; cash runway extended into Q2 2024","bullets":["Net loss of $5.1M for Q4 2022 vs net income of $1.6M in Q4 2021; full-year net loss $18.8M vs $36.1M in 2021.","Cash and cash equivalents $70.1M as of Dec 31, 2022; expects runway into Q2 2024.","Phase 3 prostate cancer trial topline data expected Q4 2024; phase 2 NSCLC data expected Q3 2023.","Paused enrollment in phase 2 pancreatic cancer trial subject to additional funding; initial data still expected Q4 2023.","CAN-3110 in recurrent HGG showed median overall survival of 11.6 months in phase 1 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010758","json":"https://secwatch.observer/filing/0000950170-23-010758.json","markdown":"https://secwatch.observer/filing/0000950170-23-010758.md","text":"https://secwatch.observer/filing/0000950170-23-010758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023010758/0000950170-23-010758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023010758/cadl-20230330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:39:57.032329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28b2499a4783122474ae69fc42f875b0dbe6e0e0","claim":"Candel Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On March 30, 2023, Candel Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023010758/0000950170-23-010758-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}